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NF-κBClinical and experimental biomedical studies have shown Type 2 diabetes mellitus (T2DM) to be a risk factor for
the development of Alzheimer's disease (AD). This study demonstrates the effect of metformin, a therapeutic
biguanide administered for T2DM therapy, on β-amyloid precursor protein (APP) metabolism in in vitro,
ex vivo and in vivo models. Furthermore, the protective role of insulin against metformin is also demonstrated.
In LAN5 neuroblastoma cells, metformin increases APP and presenilin levels, proteins involved in AD.
Overexpression of APP and presenilin 1 (Pres 1) increases APP cleavage and intracellular accumulation of β-
amyloid peptide (Aβ), which, in turn, promotes aggregation of Aβ. In the experimental conditions utilized the
drug causes oxidative stress, mitochondrial damage, decrease of Hexokinase-II levels and cytochrome C release,
all of which lead to cell death. Several changes in oxidative stress-related genes following metformin treatment
were detected by PCR arrays speciﬁc for the oxidative stress pathway. These effects of metformin were found to
be antagonized by the addition of insulin, which reduced Aβ levels, oxidative stress, mitochondrial dysfunction
and cell death. Similarly, antioxidant molecules, such as ferulic acid and curcumin, are able to revert metformin's
effect. Comparable results were obtained using peripheral blood mononuclear cells. Finally, the involvement of
NF-κB transcription factor in regulating APP and Pres 1 expressionwas investigated. Uponmetformin treatment,
NF-κB is activated and translocates from the cytoplasm to the nucleus, where it induces increased APP and Pres 1
transcription. The use of Bay11-7085 inhibitor suppressed the effect of metformin on APP and Pres 1 expression.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The high prevalence of both Alzheimer's disease (AD) and type 2
diabetes mellitus (T2DM) in the elderly population suggests that c-
oncomitant pharmacotherapy could be desirable. AD is the leading
cause of dementia in the elderly and is characterized by a gradual loss
of cognitive function. Aging is the primary risk factor for the develop-
ment of AD, and for many other pathological conditions (including
T2DM), which can obscure AD diagnosis, or interfere with AD pharma-
cotherapy. Pathohistological hallmarks of AD include widespread neu-
ronal degeneration, extracellular amyloid plaques and intracellular
neuroﬁbrillary tangles. Amyloid plaques are produced by pathological
deposition of amyloid-β peptide (Aβ) which is a small protein deriveddiabetesmellitus; APP, amyloid
al fragment beta; ROS, reactive
sitionpore;NF-κB,nuclearfactor
and Molecular Immunology
).from the sequential proteolytic cleavage of amyloid precursor protein
(APP) by β-site APP cleaving enzyme 1 (BACE1) and γ-secretase — a
multi-subunit protease complex comprised of proteins such as
resenilins 1 and 2 (PS1, PS2) [1,2]. Cleavage of APP generates a soluble
extracellular fragment, and a cell membrane-bound fragment referred
to as C-terminal fragment beta (CTF-b). Cleavage of CTF-b, by γ-
secretase, produces Aβ, the accumulation and misfolding of which in
neurons lead to the pathological cascade of AD. Fibrillar forms of Aβ
found in amyloid plaques were previously considered the major cause
of neuronal damage in AD, but Aβ soluble oligomers, known as Aβ
derived diffusible ligands (ADDLs), are now considered themore potent
neurotoxins [3,4]. The link observed between T2DM and AD [5,6]
suggests the existence of common cellular mechanisms. Insulin and
insulin-like growth factor-1 (IGF-1) have a direct effect on APP metab-
olism and Aβ clearance [7]. It has been observed that insulin inhibits
Aβ breakdown and exerts this effect via the insulin-degrading enzyme,
one of the main proteases involved in Aβ degradation [7]. Clinical ﬁnd-
ings have indicated that insulin has beneﬁcial effects on cognition in pa-
tients with dementia [8], suggesting that insulin signaling may have a
neuroprotective effect. A recent study has demonstrated that intranasal
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9]. Investigating interactions between medications for diabetes and
AD may clarify the relationship between diabetes, diabetes medica-
tions and AD. However, investigations into the potential relationship
between antidiabetic drugs and the risk of AD are not well docu-
mented, and are limited in that they are based on a handful of con-
ﬂicting reports from in vitro studies, animal models or limited
patient cohort populations [10]. Some ﬁndings indicate that metfor-
min (1,2-dimethylbiguanide hydrochloride), the widely prescribed
insulin-sensitizing drug, increases the production of Aβ [11], which
suggests that its use may promote the development of AD. Further-
more, a neuropathological study has reported that individuals treat-
ed both with insulin and oral antidiabetic drugs had a signiﬁcantly
lower amyloid plaque density [12]. A recent population-based
case–control study examined the relationship between T2DM and
administration of different antidiabetic drugs, and risk of AD devel-
opment. The results suggested that long-term users of metformin
may have a slightly higher risk of AD development relative to the
rest of the population [13]. Metformin, one of the most commonly
used antihyperglycemic agents, seems to act by triggering AMP acti-
vated protein kinase (AMPK), an enzyme that responds to alterations
in cellular energy levels [14].
The aim of this study was to determine the molecular mecha-
nisms underlying the effects of metformin on APP metabolism, and
of insulin's interference with these processes. The capacity for met-
formin to modulate APP and presenilin 1 expression via nuclear fac-
tor kappa B (NF-κB) activation was explored in order to elucidate
these processes.2. Materials and methods
2.1. Cell cultures and treatments
The neuroblastoma LAN5 cell line was used as cellular model. This
cell line exhibits neuronal characteristics, including expression of
neuroﬁlament and display of short neuritis. Cells were cultured with
RPMI 1640 medium (CELBIO) supplemented with 10% fetal bovine
serum (FBS) (GIBCO), 2 mM L-glutamine (SIGMA), and 1% antibiotics
(50 mg/ml−1 penicillin and 50 mg/ml−1 streptomycin) (SIGMA). Cells
were maintained in a humidiﬁed 5% CO2 atmosphere at 37 ± 0.1 °C.
For dose and time course experiments, LAN5 cells were treated with
12.5, 25, 50, 100 and 200 mM of metformin (SIGMA) in serum free me-
dium for 24 and 48 h, and with 0.1, 1 and 2.5 mM of metformin for 5 or
10 days. In the other experiments, LAN5 cells were treated with 50 mM
of metformin. For insulin treatment, cell cultures were treated with
metformin (50 mM) combined with insulin at different concentrations
(0.5, 1 μM) in serum free medium at 37 °C for 48 h, with 1 mM of met-
formin and with 10 and 100 nM of insulin for 5 days. H2O2 was utilized
at 2 and 4 mM for 1 h, with the higher concentration being chosen for
experiments in combination with antioxidants. Ferulic acid, a natural
antioxidant, was utilized at 25, 50, 75 and 100 μM, in which 50 and
75 μMwere chosen as the concentrations for the experimentswithmet-
formin and H2O2. Curcumin, another natural antioxidant, was dissolved
in 100% ethanol, and utilized at 2, 4 and 10 μM, in which 2 and 4 μM
were the chosen concentrations for the experiments with metformin
and H2O2. In experiments with H2O2 and metformin, the antioxidant
molecules were incubated for 1 h and 24 h respectively. A micro-
scope (Zeiss Axio Scope) with a camera (Axiocam) and 20× and
40× objectives, was utilized to analyze the morphology of the cells.
An enzyme-linked immunosorbent sandwich assay (ELISA)
(Invitrogen) was performed for quantitative detection of human β-
amyloid (1–42) in cell culture supernatants. NF-κB activator (TNF-
α) was utilized at 100 U/ml for 24 h. Bay11-7085 (Santa Cruz), an
irreversible inhibitor of IκBα phosphorylation was utilized at 0.4
and 0.8 μM for 24 h.2.2. Determination of cell viability
Cell viability was measured by MTS assay (PROMEGA). 1 × 106/ml
LAN5 cells were plated in 96 well plate and after 24 h were untreated
(control) or treated with metformin. MTS [3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphopheyl)2H-tetrazolium]
was used according to the manufacturer's instructions. After cell treat-
ments, 20 μl of the MTS solution was added to each well and incubated
with cells for 4 h at 37 °C, 5% CO2. The absorbance was read at 490 nm
with the Microplate reader WallacVictor 2 1420 Multilabel Counter
(Perkin Elmer). Resultswere expressed as the percentage ofMTS reduc-
tion relative to the control.
2.3. Total protein extraction and Western blotting
1 × 106 LAN5 cells untreated (control) or treated with metformin,
alone or with insulin or with antioxidants, H2O2 alone or with antioxi-
dants, were harvested using trypsin–EDTA and centrifuged at 500 ×g
for 5 min. After washing in PBS and centrifugation at 500 ×g for 5 min
the pellets were dissolved in solubilizing buffer (50 mM Tris–HCl,
pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 2 mM PMSF, 1 mM DTT, 0.1%
SDS) with protease inhibitor (Amersham) and phosphatase inhibitor
cocktails II and III (SIGMA). Mouse brains were homogenized in RIPA
buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 1 mM Na3VO4, 10 mM NaF,
1 mM EDTA, 1 mM EGTA, 0.2 mM phenylmethylsulfonyl ﬂuoride, 1%
Triton, 0.1% SDS, and 0.5% deoxycholate) with protease inhibitors
(Amersham) and phosphatase inhibitor cocktails II and III (SIGMA). To
remove insoluble material, cell lysates were sonicated and centrifuged
at 11,500 ×g, for 10 min. Proteins (20 μg) were resolved with NuPAGE
4–12% Bis-Tris gels (Life Technologies) and transferred onto nitrocellu-
lose ﬁlters for immunoblotting with anti-β-amyloid (1:500), anti-
presenilin 1 (1:500), anti-BACE (1:1000), anti-NF-κΒ (1:1000), anti-
VDAC (1:1000), and anti-Lamin B (1:4000) purchased from Santa
Cruz; anti-phosphorylated-AMPK (1:1000), anti-Hexokinase II
(1:1000), anti-cytochrome C (1:1000), and anti-phosphorylated NF-κΒ
(1:100) purchased from Cell Signaling; and anti-β-actin (1:1000) pur-
chased from Sigma. Primary antibodies were detected using the ECL
chemiluminescence kit (Amersham) according to the manufacturer's
instructions and using secondary antibodies conjugated to horseradish
peroxidase (1:2000) (Cell Signaling). In some instances, antibodies
were stripped from blots with Restore Western Blot Stripping Buffer
(Thermo Scientiﬁc) for 15 min at room temperature, for antibody
reprobing. Band intensities were analyzed with a gel documentation
system (BioRad). Expression was normalized with β-actin, Lamin B or
VDAC expression.
2.4. ROS generation and mitochondrial membrane potential assays
Following treatment the cells were incubated in the dark with 1 mM
dichloroﬂuorescein diacetate (DCFH-DA) in PBS (137 mM NaCl, 2.7 mM
KCl, 8 mM Na3PO4, pH 7.4) for 10 min at room temperature, then ana-
lyzedwith aﬂuorescencemicroscope (Axio Scope 2, Zeiss) and aﬂuorim-
eter (WallacVictor 2, Perkin Elmer). Mitochondrial membrane potential
was measured using a MitoProbe JC-1 Assay Kit (Molecular Probes).
After treatment the cells were incubated with 2 mM JC-1 (5,5′,6,6′-
tetrachloro-1,1′;,3,3′-tetraethylbenzimidazolyl-carbocyanine iodide)
ﬂuorescent dye in PBS for 30min at 37 °C. Themitochondrial membrane
potential disrupter CCCP (carbonyl cyanide 3-chlorophenylhydrazone)
was used at 50 μM as a control. The shift of JC-1 ﬂuorescence emission
fromred (590nm) to green (529nm)wasdeterminedwith aﬂuorimeter
(WallacVictor 2, Perkin Elmer).
2.5. Mitochondria isolation
The mitochondria fractions of untreated and treated cells were
prepared by using a Mitochondria Isolation kit (Thermo Scientiﬁc)
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ed in the kit. Brieﬂy, 2 × 106 LAN5 cells were pelleted and solubilized in
Reagent A. After incubation in ice, Reagent B was added and the sample
was centrifuged at 700 ×g for 10 min at 4 °C. The pellet was either
discarded or stored (nuclei and cell debris respectively) and the super-
natant was centrifuged at 12,000 ×g for 15min, at 4 °C. The supernatant
(cytosol)was either discarded or stored and the pellet was thenwashed
with Reagent C, then centrifuged at 12,000×g for 5min, at 4 °C. The pel-
let (mitochondrial fraction) was then stored at−80 °C, or used for pro-
tein extraction.
2.6. Peripheral blood mononuclear cell isolation
10 ml of venous blood was collected early in the morning from ten
healthy donors (age range: 30–40 years old) and peripheral bloodmono-
nuclear cell (PBMC) isolation was performed immediately. PBMCs were
isolated from heparinized blood of donors by Ficoll-Paque Plus (GE
Healthcare Bio-Sciences AB) and cultured at 105 cells/well, in a 96 well
ﬂat-bottom plate, in complete RPMI 1640 medium supplemented with
10% heat-inactivated fetal calf serum, 2 mM L-glutamine, and 100 U/ml
penicillin/streptomycin at 37 °C. PBMCs were treated with metformin
2.5, 5, 10 and 20 mM and insulin 0.25, 0.5 and 1 μM for 24 h.
2.7. Immunoﬂuorescence
1 × 106/ml LAN5 cells were cultured on Lab-Tek II Chambered
Coverglass (Nunc) and treated as described above. After washing in
PBS the cells were ﬁxed in 4% paraformaldehyde for 30 min and stored
at 4 °C. After incubationwith 3%BSA⁄PBS for 1 h, the cellswere then im-
munostained with anti-phosphorylated-NFκB (1:100; Cell Signaling)
antibody at 4 °C overnight. Afterwashing in PBS, the sampleswere incu-
bated with anti-rabbit TRITC-conjugate secondary antibody (1:300;
SIGMA). For nuclear staining, cells were incubated with Hoechst
33258 (5 μg/ml). For detection of mitochondrial activity, one vial of
Mito red was dissolved in DMSO according to the manufacturer's in-
structions (SIGMA). Living cells were incubated with 20 nM Mito red
for 5 min. The degree of red staining produced indicated mitochondrial
activity. The samples were analyzed by using a DHL ﬂuorescent micro-
scope (Leica) at excitation/emission wavelengths of 350/450 nm,
respectively. Depending on themicroscopic analysis 20× or 40× objec-
tives were used.
2.8. Preparation of cytoplasmic and nuclear extracts
Nuclear and cytoplasmic extracts were prepared using the NE-PER
Nuclear and Cytoplasmic Extraction Reagents kit (Thermo Scientiﬁc)
according to the manufacturers instructions using buffers provided in
the kit. Brieﬂy, 2 × 106 LAN5 cells were centrifuged at 500 ×g for
5 min at 4 °C. The pellet was suspended in ice-cold CERI buffer. After
10 min, CERII buffer was added and the sample was centrifuged at
16,000 ×g for 5 min at 4 °C. The supernatant (cytoplasmic extract)
was stored at-80 °C and the pellet was suspended in NER buffer. After
centrifugation at 16,000 ×g for 10min at 4 °C, the supernatant (nuclear
extract) was stored at-80 °C.
2.9. Quantitative Real-Time qPCR
Total RNA was extracted using the RNEasy Mini Kit (Qiagen). Two
nanograms of RNA was used to synthesize the ﬁrst strand cDNA using
the RT First-Strand kit (Qiagen). Synthesized cDNAs were ampliﬁed
using the RT2 SYBR Green/ROX qPCR Mastermix (Qiagen) and StepOne
Real-Time instrument (Applied Biosystem). Gene expression validation
was performed using RT2 qPCR Primer Assay for human APP, presenilin
1, NOX2, NOX5, COX1, COX2, GPX7, GSS, GSTP1, SOD3, and β-actin
(SABiosciences). Gene expression was normalized to β-actin.2.10. RT2 Proﬁler PCR array
Human oxidative stress (PAHS-065Z) focused pathway arrays RT2
Proﬁler PCR Array Human Oxidative Stress (SABiosciences) in 96-well
plate format, were used to assay gene expression changes. Samples
were prepared from pooled RNA extracted from metformin untreated
and treated LAN5 cells. Samples were added to the reaction plates
according to the manufacturer's instructions and a StepOne Real-Time
instrument (Applied Biosystem) was used to perform the array. Analy-
sis was performed using the spreadsheet provided by SABiosciences.
2.11. Mice
The animal studies were approved by Ministero della Sanità (Rome,
Italy) and in compliance with the guidelines of the European Communi-
ties Council Directive of 24 November 1986. Male C57B6/J (B6) mice,
purchased from Harlan Laboratories (San Pietro al Natisone Udine,
Italy) at 4 weeks of age, were housed under standard light (12 h
light:12 h darkness cycle) and temperature (22–24 °C) conditions.
After acclimatization (1 week), the animals were divided into two
groups (control and metformin treated). Mice were provided food and
received metformin in drinking water (2 mg/ml) for 7 days. After this
period of treatment animals were sacriﬁced by cervical dislocation.
2.12. Statistical analysis
All experiments were repeated at least three times and each ex-
periment was performed in triplicate. The results are presented as
mean ± SD. A one-way ANOVA was performed, followed by Dunnett's
post hoc test for analysis of signiﬁcance. Results with a P-value b 0.05
were considered statistically signiﬁcant, *P b 0.05 and **P b 0.02.
3. Results
3.1. Metformin increases Aβ metabolism and APP and
presenilin 1 expression
LAN5 neuroblastoma cells were used as an initial model to test the
effect of metformin on APP metabolism. Cells treated with metformin
showed differing degrees of degeneration and morphological changes
resulting in reduction of the cell body, neurites and cell number
(Fig. S1A). Decreased viability in a dose and time dependent manner
was conﬁrmed by MTS assay (Fig. S1B). Furthermore, incubation with
Hoechst 33258 revealed the presence of DNA nicks, a hallmark of apo-
ptosis, in the metformin treated sample (Fig. S1C).
To examine the effect of metformin on APP and various metabolite
expression levels, and the presence of Aβ aggregates, a Western blot
of proteins extracted from LAN5 cells treated with differing metformin
concentrations and exposure times was incubated with an anti-Aβ
antibody raised against the 42 amino-acids of Aβ. Higher metformin
concentrations correlated with increased expression of APP and, con-
sequently, the formation of Aβ fragments and aggregates (Fig. 1A). An
intriguing observation was that as metformin concentration and expo-
sure time increased, growth of larger and larger Aβ aggregates was ob-
served. In order, to analyze whether metformin also has an effect on
secretases involved in APP processing, the sameWestern blot was incu-
bated with anti-presenilin. Its expression levels increased in a dose and
time dependentmanner (Fig. 1A). In accordance with the protein levels
observed, expression of APP and presenilinmRNAs, analyzed by quanti-
tative real-time PCR (qRT-PCR), was signiﬁcantly increased in metfor-
min treated LAN5 cells relative to controls (Fig. 1B). Further, the
effects of metformin concentration have been explored for prolonged
exposure ranged from 0.1 to 2.5 mM. After 10 days of incubation the
lower dose utilized (0.1 mM) showed a rate of mortality comparable
to the rate observed at 100 mM for 24 h (Fig. S1B, E). Regarding the ef-
fect on the percentage of cell viability (Fig. S1B, E), APP and presenilin
Fig. 1.A)Analysis of APP and itsmetabolites, including Aβ42 and Aβ aggregates and presenilin 1 (Pres 1) uponmetformin treatment.Western blot of proteins extracted from LAN5 control
(C), or treated with metformin at different concentrations (12.5, 25, 50 mM) for 24 and 48 h. Uniformity of gel loading was conﬁrmed with β-actin utilized as standard. The molecular
weigh markers (in kDa) used in PAGE are indicated on the right. B) Effect of metformin on APP and presenilin 1 (Pres 1) mRNA levels. The APP and presenilin transcript levels were
determined by quantitative real-time PCR. C) Dose dependent metformin's effect at 24 h on extracellular Aβmeasured by ELISA. *P b 0.05, **P b 0.02, versus indicated groups.
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between metformin treatment with 1 mM for 5 days and with 50 mM
for 24 h (Fig. S2A, B; Fig. 1). To obtain signiﬁcant responses in a reason-
able observation time most of the following experiments were per-
formed using a concentration of 50 mM for 24 h. Furthermore, to
determine whether the Aβ generated was also secreted into the extra-
cellular environment, an ELISA assay was performed in supernatant of
LAN5 cells treated with metformin for 24 h. An increase in production
of secreted Aβ in a dose dependent manner, occurring the maximum
effect (about 2.5-fold) at 50 mM, was observed (Fig. 1C).
3.2. Insulin protects LAN5 cells against metformin toxicity
Insulin's cascade protects against Aβ-toxicity [15,16] and, in this
context, we investigated whether insulin can mediate the effects of
metformin onAPPmetabolism. LAN5 cellswithmetformin and differing
concentrations of insulin, led to a recovery of viability (Fig. 2A) and of
cell morphology (Fig. 2B). Furthermore, after the addition of insulin, a
signiﬁcant inhibition of metformin-stimulated Aβ production and
presenilin levels, in a dose-dependent manner, was observed (Fig. 2C,
D). In accordance with previous results, the increased expression of
APP and presenilin mRNA inmetformin treated LAN5 cells was reduced
by the presence of insulin, in a dose-dependentmanner, as demonstrat-
ed by qRT-PCR analysis (Fig. 2E, F). Furthermore, we determined that
lower concentrations of insulin were required for it to exert its protec-
tive role when minor metformin doses were administered for 5 days
(Fig. S3).
3.3. Insulin reduces oxidative stress and mitochondrial dysfunction
generated by metformin
Oxidative stress is one of themain causes of cell death. Insulin is able
to inhibit this process [17,18]. We investigated whether metformin's
toxicity is induced through oxidative stress that can, in turn, be antago-
nized by insulin. Fluorimetric analysis demonstrated that the presenceof intracellular ROS, increased proportionally to metformin concentra-
tion (Fig. 3A). The effect of metformin was reversed by the addition of
insulin, indicated by a dose dependentmanner decrease in DCF ﬂuores-
cence intensity (Fig. 3B). A physiologicalﬂuorescent signalwas detected
in control cells. Mitochondrial membrane potential (ΔΨm) is critical for
maintaining thephysiological function of the respiratory chain to gener-
ate ATP. To detect the status of mitochondrial membrane potential
(ΔΨm) we performed a JC-1 assay, in which membrane depolarization
is measured and presented as differing red and green ﬂuorescence in-
tensities. In samples treated with metformin and CCCP, green ﬂuores-
cence was higher than red ﬂuorescence, indicating a signiﬁcant
decrease in ΔΨm (Fig. 3C). In contrast to this, a strong decrease in
green ﬂuorescence was detected in samples in which insulin had
been added, indicating that the physiological mitochondrial mem-
brane potential was re-established (Fig. 3D). To further conﬁrm the
inhibition of metformin mitochondrial damage by insulin the cells
were stained with Mito Red dye to determine the level of respiratory
activity. Further to this, the ﬂuorescent dye Hoechst 33258 was used
to investigate whether condensed chromatin, characteristic of apo-
ptotic cells, was present. In cells treated with metformin no mito-
chondrial activity was observed. However, cells treated with both
metformin and insulin showed strong red staining, which, together
the absences of DNA nick, suggests that insulin attenuated the effect
of the drug (Fig. 3E).
The mitochondrial collapse of the ΔΨm is a typical phenomenon
following opening of the permeability transition pores (PTPs) of themi-
tochondrion. This causes the release of cytochrome C, a key event in the
mitochondrial pathway of apoptosis. To test whether metformin can af-
fect HK-II, a protein of the PTP complex, and, consequently, cytochrome
C, fractionation of LAN5 cells treated with metformin without or with
insulinwas performed to produce cytosolic andmitochondrial fractions.
A decrease in mitochondrial HK-II and cytochrome C levels was ob-
served in samples treated with metformin (Fig. 3F–H). In the presence
of insulin both HK-II and cytochrome C levels were comparable to
those of the control (Fig. 3F–H).
Fig. 2. Insulin protects neuroblastoma cells against metformin toxicity and reduces Aβ generation. A) LAN5 neuroblastoma cells treated with metformin (Met) at 50 mM alone or with
insulin (Met-Ins) at 0.5 and 1 μM, or insulin (Ins) alone for 48 h and submitted to MTS assay. The viability is expressed as the percentage as MTS reduction with respect to the control
cells. B) Representative morphological images of LAN5 untreated cells (control), or treated with metformin (Met) at 50 mM alone or combined with insulin (Met-Ins) at 1 μM, or insulin
(Ins) alone, for 48 h. Higher-magniﬁcation images of degenerated and recovered neurons are represented in the squares. Bar, 20 μm. C)Western blot of proteins extracted from LAN5 un-
treated or treated with metformin (Met) at 50 mM alone or with insulin at 0.5, 1 μM or with insulin alone and incubated with anti-APP and anti-presenilin 1 (Pres 1); uniformity of gel
loadingwas conﬁrmedwithβ-actin utilized as standard. D)Quantiﬁcation of immunoreactivitywasperformedusing densitometric analysis. Insulin inhibitsAPP and presenilin transcripts.
E, F) Effect of insulin on reducingmetformin's outcome onAPP and presenilin 1 (Pres 1)mRNA levels. TheAPP and presenilin 1 transcript levelswere determined by quantitative real-time
PCR. *P b 0.05, **P b 0.02 versus indicated groups.
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treated cells
To conﬁrm that metformin acts as a pro-oxidant molecule, we ana-
lyzed the expression of oxidant-related genes by employing gene expres-
sion proﬁling technology. We compared the expression levels of 84
genes that regulate oxidative stress, including antioxidant genes and
those involved in ROS and superoxide metabolism (Figs. S4 and 4A).
Twenty-three of the 84 genes had expression levels that were increased
or decreased by more than 2-fold in metformin treated samples relative
to the control (Fig. 4B). In addition, we validated the expression of NOX2,
NOX5, COX1, and COX2, genes associated with ROS production and of
GPX7, GSS, GSTP1, and SOD3, genes associatedwith antioxidant function
by quantitative real-time PCR (Fig. 4C, D). As shown, the observed chang-
es were always of the same order of magnitude as those obtained by PCR
Arrays andwere in agreementwith the oxidative stress status of the cells.
Therefore, oxidative stress induced by metformin up-regulates ROS me-
tabolism genes and down-regulates antioxidant genes.3.5. Metformin produces oxidative stress and increases APP
expression in PBMC
Human lymphocytes have been utilized to study inﬂammatory re-
sponse, oxidative stress, apoptosis and speciﬁc signaling in the presence
of Aβ [19,20]. To validate our observation about the injurious effect of
metformin on neuronal cultures, we treated peripheral blood mononu-
clear cells (PBMC) from healthy young people, with a range of concen-
trations (5, 10, 20 mM) of this drug. In the presence of metformin cell
viability was lowered by 35–45% relative to the control, with a weak
dose dependency (Fig. 5A). Consistent with our previous results, the
toxicity induced by metformin was antagonized by insulin addition
(Fig. 5B). Furthermore, ﬂuorimetric analysis and microscopic observa-
tion revealed increased levels of ROS, indicating that the same molecu-
lar drug response was occurred in the ex vivo system (Fig. 5C, D). As
expected, reduction in ROS was observed in the presence of insulin
(0.25, 0.5, 1 μM) (Fig. 5E). The effect on APP and presenilin expression
in PBMC was analyzed and found to be increased by metformin. This
Fig. 3.Metformin induces ROS generation and mitochondrial dysfunction in neuroblastoma cells in dose-dependent manner. A) LAN5 cells were untreated (control) or treated with
metformin (Met) (12.5, 25, 50 mM) for 24 h. B) LAN5 cells were treated with metformin (Met) at 50 mM alone or with insulin (Met-Ins) at 1 and 2.5 μM or with insulin alone (Ins
2.5 μM) for 24 h. After these treatments the cells were submitted to DCFHDA assay and ﬂuorescence was measured. C) Untreated LAN5 cells (control) or treated with metformin
(Met) (12.5, 25, 50 mM) or with CCCP, as positive control. (D) Untreated LAN5 cells (control), treated with metformin (Met) at 50 mM, with metformin and insulin (Met-Ins) at 1 and
2.5 μM, with insulin alone (Ins 2.5 μM) or with CCCP as positive control. After these treatments the cells were submitted to JC-1 assay. The histograms in C and D represent the obtained
difference between red and greenﬂuorescence intensity. E) Insulin recoversmitochondrial respiratory activity, reduced bymetformin. LAN5 cellswere untreated (control), or treatedwith
metformin (Met) at 50 mM, or with metformin and insulin (Met-Ins) at 1 μM, and incubated with Mito Red and Hoechst 33258. The images of each sample were merged. Red staining
indicates mitochondrial activity while intense blue staining indicates nuclear fragmentation. Bar, 10 μm. Metformin modulates Hexokinase II and cytochrome C levels. F) Western blot
of proteins extracted from mitochondria of untreated LAN5 cells (control) or treated with metformin (Met) (50 mM), with metformin and insulin (Met-Ins) (1 μM) or with insulin
alone (Ins) and incubated with, anti-Hexokinase II (HKII) and anti-cytochrome C (Cyt C). Uniformity of gel loading was conﬁrmed with VDAC utilized as standard. G, H) Quantiﬁcation
of immunoreactivity was performed using densitometric analysis. *P b 0.05, **P b 0.02 versus indicated groups.
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H), indicating a strong correlation in the drug response.
3.6. Antioxidants revert APP levels induced by H2O2 and metformin
To verify our observation thatmetformin affects APPmetabolism via
oxidative stress activation, we tested whether other oxidant molecules
such as H2O2 have a comparable effect. LAN5 cells were treated with
two concentrations of H2O2 and the consequent effect on APP protein
levels was evaluated by immunoblotting. As shown in Fig. 6A and B,APP levels increased in the presence of H2O2 in a dose dependent man-
ner. Following this, we tested whether antioxidant molecules could
antagonize the oxidant effect observed. For this aim we chose two dif-
ferent antioxidants ferulic acid (FA) and curcumin. FA is amolecule nat-
urally present in plant cell walls with high antioxidant and anti-
inﬂammatory properties [21]. Curcumin, a natural polyphenol extracted
from the rhizome of Curcuma longa, has a wide range of pharmacologi-
cal activities such as anticancer, antioxidant and anti-inﬂammatory ac-
tivities [22]. Optimal FA and curcumin concentration was determined
using viability experiments on LAN5 cells (Fig. S5). LAN5 cells were
Fig. 4.Oxidative stress PCR Array analysis. Untreated and treatedwithmetformin LAN5 cells were used to prepare themRNA for the PCR Array analysis. A) Three-dimensional chart taken
from SABiosciences analysis software showing the fold difference in expression levels for 84 oxidative stress-related genes (metformin vs control). Position of the genes is signiﬁed in
Fig. S2. B) Scatter Plot of relative expression levels for each gene in the two samples (metformin vs control). The ﬁgure depicts a log transformation plot of the relative expression level
of each gene (2−ΔCt) between untreated cells (x-axis) and treated cells (y-axis). The gray lines indicate a two-fold change in gene expression threshold. Red rings indicate up-regulated
genes, green rings indicate down-regulated genes. C)Histogramof somegeneswith a greater than 2-fold expression change chosen to validate PCRArray. D) Table of quantitative real time
PCR analysis (±SD) of the chosen genes.
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two different concentrations. The APP levels were then examined. As
expected the antioxidants were able to reduce the effect of both H2O2
and metformin on APP production (Fig. 6C–F).
3.7. Metformin activates NF-κB and leads to its translocation from the
cytoplasm to the nucleus
NF-κB is a key transcription factor implicated in the regulation of
many genes in both cytoprotective and apoptotic pathways. In the
conventional pathway of NF-κB activation, phosphorylation of NF-κB's
inhibitor (IκBα) releases it from NF-κB, allowing its degradation and
consequently, NF-κB activation and translocation to the nucleus. Cyto-
kines such as tumor necrosis factor (TNF) and other stressors activate
NF-κB, which translocates from the cytoplasm to the nucleus where it
initiates speciﬁc gene expression. Recent studies have indicated that
APP and presenilin expression can be regulated by NF-κB [23]. As met-
formin causes ROS production, we investigated whether it also causes
subsequent activation of NF-κB. Levels of activated NF-κB were in-
creased in LAN5 cells treated with metformin, or with TNF-α (Fig. 7A,
B). These results were conﬁrmed by immunoﬂuorescence analysis. Ac-
tiveNF-κBwas undetectable in the control cells, whereas strong expres-
sion of NF-κB was detected in the nuclei of metformin and TNF-α LAN5treated cells (Fig. 7C). As a consequence of the previous experiments,
we evaluated the shuttling of NF-κB between the cytoplasm and the
nucleus following treatment with metformin and TNF-α as a positive
control. For this aim, LAN5 cells, after the speciﬁed treatments, were
separated into cytosolic and nuclear fractions. Protein extracts were
immunoblotted with antibodies raised against total NF-κB and laminin
B, as a nuclear control. As expected, NF-κB was mainly present in the
cytoplasm fraction of control cells, whereas an increased level in the nu-
clear fraction was detected in metformin and TNF-α treated samples
(Fig. 7D, E). Consistent with the data reported that demonstrates that
metformin activates APP and presenilin gene expression, we explored
the involvement of NF-κB as their transcription factor. Bay11-7085, an
irreversible inhibitor of IκBα phosphorylation, was added at different
concentrations ofmetformin treated samples. qRT-PCR analysis showed
an inhibition both of APP, and of presenilin transcription in a dose de-
pendent manner. The higher dose, in particular, caused a reduction of
75% of APP and presenilin expression (Fig. 7F, G). This result denotes
the existence of an NF-κB dependent mechanism for metformin's effect
on Aβ generation.
Finally, we investigated whether insulin and the antioxidants used
in our earlier experiments could inhibit the effect of metformin on NF-
κB. Protein extracted from LAN5 cells treatedwithmetformin and either
insulin or FA and curcumin were immunoblotted with an antibody
Fig. 5.Metformin induces toxicity in PBMCs, via ROS generation, recovered by insulin. A) PBMCswere untreated (control) or treatedwithmetformin (Met) at different concentrations (2.5,
5, 10, 20 mM) for 24 h and submitted to MTS assay. B) PBMCs were untreated (control) or treated with metformin (Met 10mM) and with different insulin concentrations (Met-Ins 0.25,
0.5, 1 μM) or with insulin alone (Ins 1 μM) and submitted to MTS assay. Metformin produces ROS generation in PBMCs. C) PBMCs were untreated (control) or treated with metformin
(Met) at different concentrations (5, 10, 20 mM) and submitted to DCFHDA assay. D) Representative ﬂuorescent images of untreated LAN5 cells (control) or treated with metformin
(Met). Bar, 10 μm. E) PBMCs were untreated or treated with metformin (Met 10 mM) alone or with different insulin concentrations (Met-Ins 0.25, 0.5, 1 μM) or with insulin alone (Ins
1 μM) and submitted to DCFHDA assay. Metformin induces APP and presenilin expressions that are inhibited by insulin. F) Western blot of protein extracted from PBMCs untreated
(control) or treated with metformin alone (Met 10 mM) or with insulin at two concentrations (Met-Ins 0.25, 0.5 μM) or with insulin alone (Ins 0.5 μM) and incubated with anti-APP
and anti-presenilin 1 (Pres 1). Uniformity of gel loading was conﬁrmed with β-actin as standard. G, H) Quantiﬁcation of immunoreactivity, was performed using densitometric analysis.
*P b 0.05, versus indicated groups.
1053P. Picone et al. / Biochimica et Biophysica Acta 1853 (2015) 1046–1059raised against phosphorylated NF-κB. All the administered substances
were able to inhibit activation of NF-κB induced by metformin
(Fig. 8A, B). To conﬁrm our previous results, we used immunoﬂuores-
cence analysis to investigate whether active NF-κB was present into
the nucleus (Fig. 8C). Intense immunostaining was detected in the
nuclei of metformin treated LAN5 cells, whereas active NF-κB levels
were undetectable in cells treated with metformin and either insulin
or ferulic acid and curcumin, providing evidence that NF-κB activation
is induced by oxidative stress caused by metformin.
3.8. Metformin can reach the mouse brain and increase APP levels
To validate our observations obtained from neuronal cultures and
PBMC, and to verify whether the drug is able to reach the brain, we sys-
tematically treated C57B6/J mice with metformin (2 mg/ml in drinking
water) for 7 days, a dose comparable to 300mg/kg/day [11]. To conﬁrm
deliver of metformin to the brain we tested its effect on AMP-activated
protein kinase (AMPK). AMPK is a major cellular regulator of lipid and
glucose metabolism, and considered one of the main molecular targets
of metformin [14]. Levels of AMPK's phosphorylated form were corre-
lated with increased levels of APP and BACE indicating modiﬁcation of
APP metabolism by metformin in the mouse brain (Fig. 8A–D). Finally,expression of APP and presenilin mRNAs, quantiﬁed using qRT-PCR,
was signiﬁcantly increased in metformin treated mice relative to the
control (Fig. 8E), suggesting that the drug exerts a similar effect
in vitro, ex vivo and in vivo.
4. Discussion
The molecular mechanism that may link metformin use with in-
creased risk of AD development, the protective role that insulin and/or
antioxidants may have when used in combination with metformin,
and the involvement of the transcription factor NF-κB in APP and
presenilin modulation in these processes was investigated.
Ourﬁndings indicate thatmetformin upregulates APP and presenilin-
1 gene expression and consequently increases intra- and extra-cellular
Aβ via a mechanism involving mitochondrial dysfunction, free radical
generation and cell death. In addition, since it is well known that oxida-
tive stress induces Aβ peptide production that, in turn, triggers oxidative
stress, our studies suggests that metformin contributes to the vicious
cycle by which Aβ self-feeds its own production [24,25]. Moreover, al-
though the precise mechanism is undetermined we cannot exclude
that the high concentration of Aβ peptide induces its conformational
change and consequent aggregation. Furthermore, the increase of APP
Fig. 6.Antioxidants inhibit production of APP. A)Western blot of proteins extracted from LAN5 cells treatedwith H2O2 at different concentration and incubatedwith anti-APP. C)Western
blot of proteins extracted fromLAN5 cells treatedwithH2O2 (4mM) and FA (50, 75 μM)and curcumin (2, 4 μM)at different concentrations and incubatedwith anti-APP. E)Western blot of
proteins extracted fromLAN5 cells treatedwithMetformin (50mM)andFA (50, 75 μM)and curcumin (2, 4 μM)at different concentrations and incubatedwith anti-APP.Uniformity of gels
loading was conﬁrmed with β-actin utilized as standard. B, D, F) Quantiﬁcation of immunoreactivity, was performed using densitometric analysis; *P b 0.05, **P b 0.02 versus indicated
groups.
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Some studies suggest that insulin inﬂuences APP-Aβ metabolism by
accelerating trafﬁcking from the trans-Golgi network to the plasma
membrane [26], and that insulin administration suppresses the expres-
sion of APP, presenilins 1 and 2, and Gsk-3β in PBMC of obese type 2
diabetic patients [27].
Metformin acts as an oxidant molecule, having the same conse-
quence of H2O2 on APPmetabolismwhich is antagonized by antioxidant
molecules such as FA and curcumin. This result is in agreementwith the
experimental observation that antioxidants are able to reduce Aβ− in-
duced oxidative stress [28–31]. Metformin induces mitochondrial
membrane depolarization (decrease of ΔΨm) in contrast, the presence
of insulin leads to repolarization of the mitochondrial membrane(recovery ofΔΨm).Metformin has been shown to inhibit mitochondrial
complex I activity leading to impairment of mitochondrial function [32,
33] and also to prevent PTP opening in both permeabilized and intact
cells [34,35]. However, other authors observed that metformin exacer-
bates PTP opening in isolated rat mitochondria, predisposing to cell
death [36,37]. As HK-II is a constituent of mitochondrial PTP, its reduc-
tion following metformin administration, suggests that the drug may
induce cytochrome C release. Thus, metformin induces mitochondrial
dysfunction that together to oxidative stress is one of the primary
events of AD onset. However, these effects of metformin were reverted
with the addition of insulin. Insulin can exert a potent redox-regulating
role through the attenuation of ROS generation and the elimination of
ROS and reactive nitrogen species (RNS) by exercising a scavenger
Fig. 7.Nuclear-cytoplasmic shuttling ofNF-κB. A)Westernblot of proteins extracted fromLAN5 cells untreated (control) ormetformin-treated (Met) at 25 and 50mMor treatedwith TNF-
α and incubated with anti-phospho-NF-κB (p-NFκB). Uniformity of gel loading was conﬁrmed with β-actin as standard. B) Quantiﬁcation of immunoreactivity was performed using
densitometric analysis. C) Immunoﬂuorescence of LAN5 untreated (control) or metformin (Met) and TNF-α treated cells, incubated with anti-phospho-NF-κB (p-NFκB) (red staining)
and Hoechst 33258 (blue staining) and examined by ﬂuorescent microscopy. Merged images of anti-phospho-NF-κB and Hoechst 33258 staining are shown. Bar, 10 μm. D) Western
blot of proteins extracted from LAN5 cells untreated (control) or metformin (Met) and TNF-α treated and subjected to subcellular fractionation in cytoplasmic (C) and nuclear
(N) fractions and incubated with anti-NF-κB (NFκB). The relative purity of the nuclear and cytoplasmic fractions was conﬁrmed by probing with the nuclear marker laminin
B. E) Quantiﬁcation of immunoreactivity was performed using densitometric analysis. NF-κB inhibitor reduces APP and presenilin 1 transcription induced by metformin. LAN5 cells
were untreated (control) or treated with metformin (Met) alone or with metformin with two Bay11-7085 concentrations or with Bay11-7085 alone and the APP (F) and presenilin 1
(Pres 1) (G) mRNA were quantized. Transcript levels were determined by quantitative real-time PCR. *P b 0.05 **P b 0.02 versus indicated groups.
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tion, has been found to be involved in the antagonismof oxidative stress
induced by Aβ through inhibition of FoxO3a, a pro-apoptotic transcrip-
tion factor stimulated by ROS generation [16]. Similarly, insulin attenu-
ates mitochondrial dysfunction in neuronal cells and in the kidney and
heart isolated from diabetic rats [16,39,40]. Further evidence that met-
formin induces cell degeneration via oxidative stress is in the modula-
tion of genes related to oxidative stress in AD. The stressed status of
the cell was evident in the modulation of these genes, since genes in-
volved in ROS production were up-regulated genes involved in anti-
oxidant function were down-regulated. NADPH oxidase (NOX), a
mitochondrial membrane enzyme, contributes to generation of super-
oxide and other downstream ROS [41]. In particular, NOX2 was found
localized in the cerebral cortex and hippocampus of the AD brain [42].
Cyclooxygenase (COX) is an enzyme that converts arachidonic acid to
prostaglandins with two known isoforms. COX-1 plays a constitutive“housekeeping” role. COX-2, is an inducible isoform, the expression of
which has been correlated with amyloid plaque density [43]. Physio-
logical antioxidant molecules counteract oxidative stress. Glutathione
peroxidase (GPx), superoxide dismutase (SOD), and catalase are the
main enzymes involved in cellular protection against damage due to
oxygen-derived free radicals [44]. GPxs (1–8) are an enzyme family
that protects against oxidative damage. SODs are a class of enzymes
that catalyze the breakdown of the superoxide anion into oxygen and
hydrogen peroxide. In a case–control study, a decrease of GPx, SOD
and catalase activity was detected in subjects with AD [44].
Preliminary study on PBMCs validated our ﬁndings on neuronal cells.
In this ex-vivo system, administration of metformin caused a reduction
in cell viability due to increased oxidative stress which was attenuated
by the addition of insulin. This suggests that combination of these two
substances may be beneﬁcial. Many studies have suggested that inter-
action between the central nervous system (CNS) and systemic immune
Fig. 8. Insulin and antioxidants inhibit the action of metformin onNF-κB activation. A)Western blot of LAN5 cells untreated (control), treatedwithmetformin (Met 50mM) alone, or with
insulin (Met-Ins 1 μM), ferulic acid (Met-FA 75 μM)or curcumin (Met-Curc 4 μM)and incubatedwith anti-phospho-NF-κB (p-NFκB). Uniformity of gel loadingwas conﬁrmedwithβ-actin
as standard. B)Quantiﬁcation of immunoreactivitywasperformedusing densitometric analysis. **P b 0.02 versus indicated groups. C) Immunoﬂuorescence of LAN5untreated (control), or
treated with metformin at 50 mM (Met) alone, with metformin and insulin at 1 μM (Met-Ins) with metformin and curcumin at 4 μM (Met-Curc) or with metformin and ferulic acid at
75 μM (Met-FA) and incubated with anti-phospho-NF-κB (p-NFκB) (red staining) and Hoechst 33258 (blue staining) then examined by ﬂuorescent microscopy. Merged images of
anti-phospho-NF-κB and Hoechst 33258 staining are shown. Bar, 10 μm.
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induce the translocation of CNS proteins, such as Aβ, or inﬂammatory
mediators, across the blood–brain-barrier (BBB)whichmay lead to a sys-
temic immune reaction and the recruitment of myeloid or lymphocytic
cells into the CNS. Thus, the effect of drugs on lymphocytes may affect
the integrity CNSbehavior. Recently,multivariate analysis of cell cycle ac-
tivity both in AD lymphocytes and an experimental model has demon-
strated that disturbance occurs simultaneously in CNS and peripheral
cells, suggesting that analysis of PMBCs may be useful in early diagnosis
of AD [46,47].
Some experimental studies indicate that APP and presenilin expres-
sion can be regulated by the transcription factor NF-κB [23]. NF-κB is aubiquitous transcription factor activated by inﬂammation and oxida-
tive, and other cellular stresses [48]. This activation results in a pro-
tective response aimed at restoring cellular homeostasis, which can
become deleterious if activation is chronic. Several in vivo studies
have suggested that Aβ production is dependent on NF-κB activation.
In transgenic mice NF-κB activation has been shown to increase APP
levels and BACE1 promoter andγ-secretase activities [49]. Furthermore,
inhibition of NF-κB can reduce the plaque burden and improve the
learning andmemory deﬁcits inmice. In contrast, in vitro studies in pri-
mary cultured neurons have demonstrated that Aβmay activate NF-κB
by promoting nuclear translocation of its p50 and p65 subunits,
suggesting the existence of a feedback control in which Aβ activates
Fig. 10. A model to link metformin, Aβ production and cell degeneration. Exposure to metformin inhibits mitochondrial activity, induces ROS generation and decreases HK-II levels
permitting perhaps PTP opening and cytochrome C (Cyt C) release, which lead to cell death. ROS production induces NFκB activation, which once dissociated from Ik B, translocates to
the nucleus where it activates APP and presenilin 1 (PRES) gene transcription. Use of Bay11-7085 inhibits gene transcription induced by NFκB translocation. Increased APP and presenilin
1 levels lead to APP cleavage and Aβ production and aggregation. Aβ produces additional ROS that promote the translocation of NFκB to the nucleus, leading to the production of new APP
and presenilin 1.
Fig. 9.Metformin activates AMPK, BACE1 and APP in mice. A) Western blot of brain lysates from C57BL6/J mice after drinking metformin (2 mg/ml) for 7 days and incubated with anti-
pAMPK, anti-BACE1 and anti-APP. Uniformity of gel loading was conﬁrmed with β-actin utilized as standard. B, C, D) Quantiﬁcation of immunoreactivity was performed using
densitometric analysis. E) Effect of metformin on APP and presenilin 1 (Pres-1) mRNA levels. APP and presenilin 1 (Pres 1) transcript levels were determined by quantitative real-time
PCR. n = 4 animals in each group. *P b 0.05, versus indicated groups.
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cently, experiments correlating NF-κB activation with APP expression,
and with β- and γ-secretase expression, have demonstrated that,
under physiological conditions, NF-κB triggers a repressive effect on
Aβ-production, regulating Aβ-homeostasis, whereas under pathological
conditions increases Aβ production [23]. Data reported here indicate
that metformin contributes to NF-κB activation. In control cells, NF-κB
is retained in the cytoplasm, presumably bound to its inhibitor Ik B.
After exposure to metformin, NF-κB is activated and translocates into
the nucleus where it initiates APP and presenilin transcription as dem-
onstrated by blocking their transcription through Bay11-7085 inhibitor.
However, even if our study does not establish whether NF-κB-
associatedAPP andpresenilin transcription is direct or involves intracel-
lular intermediates, it is clear that metformin induced oxidative stress
triggers NF-κB activation, which is inhibited by insulin and antioxidant
molecules such as ferulic acid and curcumin.
Finally, we demonstrated that metformin is able to reach mouse
brain as revealed by activation of AMPK one of the identiﬁedmetformin
molecular target, demonstrating the ability of the drug to cross the BBB.
The dose utilized for the treatment of themicewas deduced by those
obtained by Chen et al. [11]. The authors found by the use of liquid chro-
matography in the same mouse strain (C57B6/J), that after 2 mg/ml
administration of metformin its concentration in the plasma reach
about 2 μM and in the brain about 1 μM, that results to be below the
10–40 μM reported in human plasma [14]. This dose was observed to
up-regulates APP, BACE and presenilin in rodent brain, suggesting that
this diabetes medication may cause severe side effects on accelerating
AD progression.
We propose a model (Fig. 10) in which metformin induces ROS
production, mitochondrial dysfunction, modulates HK-II expression
potentially allowing opening of PTP and cytochrome C release, all
of which lead to cell death. Cellular dysfunction is also promoted
by up-regulation of ROS production genes and down-regulation of
antioxidant genes. Induced oxidative stress activates NF-κB, which
translocates to the nucleus where it triggers APP and presenilin
gene expression. Increased APP and presenilin levels induce APP
cleavage, Aβ production and aggregation. In a vicious circle Aβ,
then cause the production of ROS which again promote the transfer
of NF-κB to the nucleus.5. Conclusions
Metformin induces an increase in the expression and processing of
APP that is counteracted by insulin. Insulin also attenuates oxidative
stress induced by metformin, as do antioxidants. Administration of
both insulin and metformin recovers physiological conditions, suggest-
ing a synergistic effect. The relationship identiﬁed between the key
pathogenic peptide of AD andmetformin/insulin is clearly of great inter-
est andmay have important implications for the treatment of T2DMand
AD.However, large clinical trials are necessary to conﬁrm and clarify the
therapeutic efﬁcacy of these compounds.Conﬂict of interests
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